Day: May 6, 2020

Paris, May 6, 20201Q20 resultsPositive earnings capacity1 despite an unprecedented market contextReported net income at €(204)m in 1Q20 impacted by the Coface transaction announcement2 as well as IFRIC 21Basel 3 fully-loaded CET1 ratio1 at 11.4%, +310bps above regulatory requirementsQuarter marked by mechanical market effects (linked to the COVID-19 context) thus mostly reversible:~€(290)m net revenue impact o/w ~€160m reversible (XvA, seed money in asset management)~(90)bps CET1 ratio impact o/w ~70bps reversible (OCI, PVA, Market and CVA RWA)A DIVERSIFIED ASSET-LIGHT MODEL DEDICATED TO CLIENTS’ NEEDSUNDERLYING NET REVENUES3 EXCLUDING CVA/DVA AT €1.9BN IN 1Q20 (-3% YOY)AWM: Resilient results, fee rate and flow dynamicsStrength of our active asset management model with underlying net revenues3 flat YoY in 1Q20 despite some mark-downs...

MIAMI, FL, May 06, 2020 (GLOBE NEWSWIRE) —  via NEWMEDIAWIRE — Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a global technology and value-added solutions group that supports electronic payments acceptance in a multi-channel environment including point-of-sale (“POS”), e-commerce and mobile devices, today announces that its Board of Directors has authorized the Company to explore strategic alternatives for its business in order to unlock shareholder value.“Net Element has optimized operations company-wide and implemented efficiencies, achieving cost savings.  At the same time, it appears that the public markets do not appropriately recognize the value of our business.  As a result, our Board of Directors has decided to explore strategic alternatives to further unlock value for its shareholders,” commented...

AttachmentGOFORE_6.5_trades

LiiteGOFORE_6.5_trades

CYBER1 Applies For Company Reorganisation, Whilst Continuing Operations London United Kingdom – 06 May 2020 – Cyber Security 1 AB (Publ) (the “Company”) (“CYBER1”) (Nasdaq First North: CYB1), has today announced that, in light of current general trading conditions, the Company has decided to apply to the Stockholm District Court to approve an application for admission into a company reorganisation process.   Following formal approval of admission, the CYBER1 group will throughout the reorganisation process trade as normal and such process will not affect the status of the Company as a listed entity on the Nasdaq First North Growth Market exchange.It is anticipated that the process may last up to a period of 3 months during which period the Company will benefit from a moratorium from any formal action by a creditor against the Company.  The...

LiiteSCANFIL_6.5_trades

AttachmentSCANFIL_6.5_trades

Named Top 10 Community Bank NationwideBIRMINGHAM, Ala., May 06, 2020 (GLOBE NEWSWIRE) — ServisFirst Bancshares, Inc. (NASDAQ: SFBS) announced today that it has received the 2019 Raymond James Community Bankers Cup, which recognizes the top 10 percent of community banks. For the sixth year in a row, ServisFirst Bancshares has been ranked in the top ten community banks.ServisFirst Bancshares ranked ninth out of 255 community banks nationwide that are exchange-traded domestic banks with assets between $500 million and $10 billion as of December 31, 2019. Each bank’s performance was judged by various metrics regarding profitability, operational efficiency and the balance sheet.  The six financial performance and stability measures include nonperforming assets to loans and real estate owned, five-year average core deposit percentage,...

LYON, Frankreich und CAMBRIDGE, Massachusetts, May 06, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq und Euronext: ERYP), ein klinisch forschendes biopharmazeutisches Unternehmen, das innovative Therapien entwickelt, bei denen Wirkstoffe in roten Blutkörperchen eingekapselt werden, hat heute bekannt geben, dass es Teil von EVIDENCE sein wird, einem öffentlich-privaten Konsortium, das von der Europäischen Union im Rahmen des Programms Horizont 2020 unterstützt wird.Das EVIDENCE-Konsortium besteht aus führenden Experten im Bereich der Erythrozytenforschung und wird untersuchen, wie Erythrozyten von ihrer extrazellulären Umgebung beeinflusst werden. Dies ist ein wichtiger Aspekt bei der Entwicklung von Erythrozyten-basierten Therapien. Das EVIDENCE-Konsortium wird das Verhalten von Erythrozyten unter physiologischen Flussbedingungen,...